This text is provided for reference. The official version is published by the Turkish Medicines and Medical Devices Agency (TİTCK).
Section I – Purpose, Legal Basis, Scope and Definitions
1.1. Purpose
The purpose of this guideline is to set out the procedures and principles for work carried out under reliance practices in pharmacovigilance activities.
1.2. Legal basis
This guideline has been prepared on the basis of Article 23 of the Regulation on the Safety of Medicinal Products, which entered into force on publication in Official Gazette No. 28973 of 15.04.2014, and of the paragraph added by Article 8 of the Regulation Amending the Regulation on the Safety of Medicinal Products, published in Official Gazette No. 31899 of 21.07.2022.
1.3. Scope
This guideline covers the use, as guidance for the work of the Agency, of pharmacovigilance assessments made by the competent authorities that are founding or standing members of the ICH (International Council for Harmonisation), the Australian Therapeutic Goods Administration (TGA), the UK Medicines and Healthcare products Regulatory Agency (MHRA) or the World Health Organization Uppsala Monitoring Centre.
1.4. Definitions
The definitions in the Good Pharmacovigilance Practices guidelines and in the related legislation apply. In addition:
- Reliance: the act whereby the regulatory authority in one jurisdiction takes into account, or gives significant weight to, assessments or other trusted information produced by another regulatory authority or a trusted institution when reaching its own decision;
- Agency: the Turkish Medicines and Medical Devices Agency (TİTCK);
- VigiFlow: the web-based pharmacovigilance management system of the World Health Organization, with easy-to-follow workflows, which uses integrated standardised medical terminologies such as the WHO Drug Dictionary and MedDRA.
Section II – Reliance practices in pharmacovigilance
2.1. Reliance in pharmacovigilance
When taking its own decisions on medicine safety, the Agency may, under reliance, take into account assessments made by other medicines authorities with comparable standards or by regional or international organisations, and may share information with them. The Agency nevertheless remains independent, responsible and accountable for the decisions it takes.
2.1.1. Reliance on processes, tools and methods
This covers reliance practices concerning the processes, tools and methods used, for example VigiFlow, the CIOMS I form, the periodic benefit-risk evaluation report, the risk management plan and direct healthcare professional communications.
2.1.2. Reliance on product-specific regulatory activities
This level of reliance requires the medicinal products concerned to be identical or sufficiently similar in terms of composition, indications, conditions of use and so on.
2.1.2.1. Reliance on approved product information
This covers reliance on the risk management plan, risk minimisation materials, direct healthcare professional communication materials, the summary of product characteristics and the patient information leaflet.
2.1.2.2. Reliance on post-authorisation safety study results and signal assessments
This covers reliance on the results of post-authorisation safety studies and on signal assessments.
Revision history
| Revision No | Revision date | Reason and explanation |
|---|---|---|
| 1 | 15.11.2022 | Format updated |
